Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions

20 Nov 2020

Abstract excerpt

Abstract Sickle cell disease (SCD) results from a hemoglobin (Hb) mutation βGlu6 → βVal6 that changes normal Hb (HbA) into sickle Hb (HbS). Under hypoxia, HbS polymerizes into rigid fibers, causing red blood cells (RBCs) to sickle; leading to numerous adverse pathological effects. The RBC sickling is made worse by the low oxygen (O2) affinity of HbS, due to elevated intra-RBC concentrations of the natural Hb...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythrocyte Function and Pathophysiology
Share to Hemoglobinopathies and Related Disorders
Share to Neonatal Health and Biochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33219275
DOI: 10.1038/s41598-020-77171-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditionsPMID 33219275Read ↗

Osivelotor for the treatment of sickle cell diseaseSemantic proximity Read ↗

Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular levelSemantic proximity Read ↗

Targeting sickle cell disease root-cause pathophysiology with small moleculesSemantic proximity Read ↗

Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches.Semantic proximity Read ↗

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell DiseaseSemantic proximity Read ↗

Sickle Cell Anemia and Antisickling Agents Then and NowSemantic proximity Read ↗

Research in Sickle Cell Disease: From Bedside to Bench to BedsideSemantic proximity Read ↗

Pathophysiological-Based Approaches to Treatment of Sickle Cell DiseaseSemantic proximity Read ↗

Phenotypic screening of the ReFrame Drug Repurposing Library to discover new drugs for treating sickle cell diseaseSemantic proximity Read ↗

Hope on the Horizon: New and Future Therapies for Sickle Cell DiseaseSemantic proximity Read ↗

Current and emerging treatments for sickle cell diseaseSemantic proximity Read ↗

Sickle Cell DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.